These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

887 related articles for article (PubMed ID: 33651193)

  • 1. Circulating low CD4
    Cao X; Kong YL; Wang L; Liang JH; Xia Y; Zhu HY; Fan L; Jiang SH; Liu H; Li JY; Xu W
    Ann Hematol; 2021 Apr; 100(4):995-1002. PubMed ID: 33651193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib-based chemotherapy for patients with Waldenström macroglobulinemia: a single-center experience.
    Liu Z; Jiang S; Gu J; Liu H; Song G; Cao X
    Ann Hematol; 2023 Jan; 102(1):167-174. PubMed ID: 36374339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating Low Absolute CD4+ T Cell Counts May Predict Poor Prognosis in Extranodal NK/T-Cell Lymphoma Patients Treating with Pegaspargase-Based Chemotherapy.
    Zhang YP; Zhang R; Zhu HY; Wang L; Wu YJ; Liang JH; Shi WY; Liu H; Xu W; Li JY
    Cancer Res Treat; 2019 Jan; 51(1):368-377. PubMed ID: 29764116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN).
    Dimopoulos MA; García-Sanz R; Gavriatopoulou M; Morel P; Kyrtsonis MC; Michalis E; Kartasis Z; Leleu X; Palladini G; Tedeschi A; Gika D; Merlini G; Kastritis E; Sonneveld P
    Blood; 2013 Nov; 122(19):3276-82. PubMed ID: 24004667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.
    Treon SP; Ioakimidis L; Soumerai JD; Patterson CJ; Sheehy P; Nelson M; Willen M; Matous J; Mattern J; Diener JG; Keogh GP; Myers TJ; Boral A; Birner A; Esseltine DL; Ghobrial IM
    J Clin Oncol; 2009 Aug; 27(23):3830-5. PubMed ID: 19506160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II Bayesian sequential clinical trial in advanced Waldenström macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasone.
    Leblond V; Morel P; Dilhuidy MS; Leleu X; Soussain C; Leprête S; Dreyfus B; Dartigeas C; Mahé B; Anglaret B; Pégourié B; Besson C; Aurran T; Vekhoff A; Tournilhac O; Banos A; Oya H; Lejeune J; Ouzegdouh M; Chevret S;
    Leuk Lymphoma; 2017 Nov; 58(11):2615-2623. PubMed ID: 28395585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum CXCL13 level is related to treatment response and predicts disease prognosis in Waldenström macroglobulinemia.
    Chen J; Jia MN; Cai H; Li ZP; Li J; Zhou DB; Cao XX
    Ann Hematol; 2024 Sep; 103(9):3667-3675. PubMed ID: 38448788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Correlation of CD4
    Li YL; Qin XQ; Guo LY; Hou XX; Chao Y; Ma YP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Aug; 32(4):1129-1135. PubMed ID: 39192409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical Significance of Detecting CD4
    Liu W; Zhagn GX; Shi WZ; Dong L; Liu H; Shen XL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):449-454. PubMed ID: 28446291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia.
    Castillo JJ; Gustine JN; Meid K; Dubeau TE; Severns P; Xu L; Yang G; Hunter ZR; Treon SP
    Br J Haematol; 2018 Apr; 181(1):77-85. PubMed ID: 29468652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia.
    Paludo J; Abeykoon JP; Shreders A; Ansell SM; Kumar S; Ailawadhi S; King RL; Koehler AB; Reeder CB; Buadi FK; Dispenzieri A; Lacy MQ; Dingli D; Witzig TE; Go RS; Gonsalves WI; Kourelis T; Warsame R; Leung N; Habermann TM; Hayman S; Lin Y; Kyle RA; Rajkumar SV; Gertz MA; Kapoor P
    Ann Hematol; 2018 Aug; 97(8):1417-1425. PubMed ID: 29610969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Negative prognostic impact of low absolute CD4
    Zhang XY; Xu J; Zhu HY; Wang Y; Wang L; Fan L; Wu YJ; Li JY; Xu W
    Cancer Sci; 2016 Oct; 107(10):1471-1476. PubMed ID: 27465799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low absolute CD4
    Gu Y; Jin Y; Ding J; Yujie W; Shi Q; Qu X; Zhao S; Li J; Lijuan C
    Leuk Lymphoma; 2020 Aug; 61(8):1869-1876. PubMed ID: 32324088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High plasma D-dimer level is a poor prognostic factor for patients with waldenström macroglobulinemia.
    Cao X; Kong YL; Wang L; Zhu HY; Liang JH; Xia Y; Fan L; Shi WY; Liu H; Li JY; Xu W
    Leuk Lymphoma; 2020 May; 61(5):1140-1146. PubMed ID: 31928271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deepening of response after completing rituximab-containing therapy in patients with Waldenstrom macroglobulinemia.
    Castillo JJ; Gustine JN; Keezer A; Meid K; Flynn CA; Dubeau TE; Chan G; Chen J; Demos MG; Guerrera ML; Jimenez C; Kofides A; Liu X; Munshi M; Tsakmaklis N; Patterson CJ; Xu L; Yang G; Hunter ZR; Treon SP
    Am J Hematol; 2020 Apr; 95(4):372-378. PubMed ID: 31868242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of pre-treatment T lymphocyte subsets in patients with extranodal natural killer/T-cell lymphoma.
    Lu X; Huang K; Chen S; Ji X; Li P
    Ann Hematol; 2024 Nov; 103(11):4621-4635. PubMed ID: 39196374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.
    Kapoor P; Ansell SM; Fonseca R; Chanan-Khan A; Kyle RA; Kumar SK; Mikhael JR; Witzig TE; Mauermann M; Dispenzieri A; Ailawadhi S; Stewart AK; Lacy MQ; Thompson CA; Buadi FK; Dingli D; Morice WG; Go RS; Jevremovic D; Sher T; King RL; Braggio E; Novak A; Roy V; Ketterling RP; Greipp PT; Grogan M; Micallef IN; Bergsagel PL; Colgan JP; Leung N; Gonsalves WI; Lin Y; Inwards DJ; Hayman SR; Nowakowski GS; Johnston PB; Russell SJ; Markovic SN; Zeldenrust SR; Hwa YL; Lust JA; Porrata LF; Habermann TM; Rajkumar SV; Gertz MA; Reeder CB
    JAMA Oncol; 2017 Sep; 3(9):1257-1265. PubMed ID: 28056114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective analysis of prognostic factors for Waldenstrӧm macroglobulinemia: a multicenter cooperative study in Japan.
    Saito A; Isoda A; Kojima M; Yokohama A; Tsukune Y; Sasaki M; Ito S; Ohtsu A; Koike M; Murayama K; Moriya K; Tamura H; Matsumoto M; Nakahashi H; Tanosaki S; Sakura T; Kawamura T; Miyanaga T; Nakamura N; Murakami H; Handa H; Tsukamoto N
    Int J Hematol; 2017 Nov; 106(5):681-690. PubMed ID: 28687991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose bortezomib and dexamethasone as primary therapy in elderly patients with Waldenstrӧm macroglobulinemia.
    Zhang YP; Yang X; Lin ZH; Wang XF; Cao X; You XF; Huang HM; Shi WY; Liu H
    Eur J Haematol; 2017 Dec; 99(6):489-494. PubMed ID: 28801984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia.
    Paludo J; Abeykoon JP; Kumar S; Shreders A; Ailawadhi S; Gertz MA; Kourelis T; King RL; Reeder CB; Leung N; Kyle RA; Buadi FK; Habermann TM; Dingli D; Witzig TE; Dispenzieri A; Lacy MQ; Go RS; Lin Y; Gonsalves WI; Warsame R; Lust JA; Rajkumar SV; Ansell SM; Kapoor P
    Br J Haematol; 2017 Oct; 179(1):98-105. PubMed ID: 28786474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.